{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:56:39Z","timestamp":1786373799641,"version":"build-2736575974"},"reference-count":50,"publisher":"Index Copernicus","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol Przegl Chir"],"published-print":{"date-parts":[[2026,2,12]]},"abstract":"<ns3:p>&lt;b&gt;Introduction:&lt;\/b&gt; Pancreatic ductal adenocarcinoma (PDAC) is one of the most common causes of cancer mortality worldwide, and most patients develop local and\/or distant recurrence at some point during follow-up. &lt;br&gt;&lt;br&gt;&lt;b&gt;Aim:&lt;\/b&gt; This review aims to present the follow-up protocols used in Poland and worldwide for patients undergoing surgical treatment for PDAC. &lt;br&gt;&lt;br&gt;&lt;b&gt;Material and methods:&lt;\/b&gt; The analysis included studies on oncological follow-up following surgical treatment for pancreatic adenocarcinoma. After searching PubMed, Scopus, and Google Scholar databases using the terms \"pancreatic adenocarcinoma recurrence\", \"surveillance after pancreatic adenocarcinoma resection\u201d, \"postopererative follow-up for pancreatic adenocarcinoma\", 50 articles were ultimately qualified for analysis. &lt;br&gt;&lt;br&gt;&lt;b&gt;Results:&lt;\/b&gt; Currently, there are no unified international standards for postoperative follow-up for PDAC. Furthermore, standardized national guidelines do not exist in Poland; thus, the optimal modality and duration of surveillance remain undefined. Furthermore, the impact of early detection and treatment of recurrence on survival and quality of life is unknown. Early detection of recurrence potentially offers greater treatment options due to systematic improvements in the treatment of local recurrence and distant metastases (DM), but it may also be associated with increased economic burden on \u201cthe payer\u201d (healthcare system), without clearly translating into benefits resulting from longer survival. Currently, there are no clear recommendations on this issue - it seems necessary to conduct prospective studies to assess whether increased postoperative surveillance can translate into improved survival of patients with PDAC. &lt;br&gt;&lt;br&gt;&lt;b&gt;Conclusions:&lt;\/b&gt; Multidisciplinary collaboration in developing uniform, nationwide oncological surveillance principles can enable effective supervision of patients with PDAC and bring health benefits. &lt;br&gt;&lt;br&gt;&lt;b&gt;The importance of this work for the development of the field:&lt;\/b&gt; This summary of the applicable guidelines and the proposed corrective actions proposed by the authors can translate into progress and improved treatment outcomes in this challenging therapeutic area.<\/ns3:p>","DOI":"10.5604\/01.3001.0055.6328","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:56:52Z","timestamp":1770973012000},"page":"39-45","source":"Crossref","is-referenced-by-count":0,"title":["The realities of oncological surveillance after surgery for pancreatic adenocarcinoma in Poland and worldwide \u2013 a narrative review"],"prefix":"10.5604","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-5391","authenticated-orcid":false,"given":"Magdalena","family":"Gajda","sequence":"first","affiliation":[{"name":"Department and Clinic of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2283-0286","authenticated-orcid":false,"given":"Ewa","family":"Grudzi\u0144ska","sequence":"additional","affiliation":[{"name":"Department and Clinic of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Zielonka","sequence":"additional","affiliation":[{"name":"Department and Clinic of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2206-3144","authenticated-orcid":false,"given":"S\u0142awomir","family":"Mrowiec","sequence":"additional","affiliation":[{"name":"Department and Clinic of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3689","reference":[{"key":"637053r1","doi-asserted-by":"crossref","unstructured":"Siegel R.L., Miller K.D., Jemal A.: Cancer statistics, 2020. CA Cancer J Clin.,2020; 70(1): 7\u201330. doi: 10.3322\/caac.21590.","DOI":"10.3322\/caac.21590"},{"key":"637053r2","doi-asserted-by":"crossref","unstructured":"Rahib L., Smith B.D., Aizenberg R. et al.: Projecting cancer incidence and deathsto 2030: the unexpected burden of thyroid, liver, and pancreas cancers inthe United States. Cancer Res., 2014; 74(11): 2913\u20132921. doi: 10.1158\/0008-5472.CAN-14-0155.","DOI":"10.1158\/0008-5472.CAN-14-0155"},{"key":"637053r3","doi-asserted-by":"crossref","unstructured":"Latenstein A.E.J., van der Geest L.G.M., Bonsing B.A. et al.: Nationwide trendsin incidence, treatment and survival of pancreatic ductal adenocarcinoma. EurJ Cancer., 2020; 125: 83\u201393. doi: 10.1016\/j.ejca.2019.11.002.","DOI":"10.1016\/j.ejca.2019.11.002"},{"key":"637053r4","doi-asserted-by":"crossref","unstructured":"Conroy T., Hammel P., Hebbar M. et al.: FOLFIRINOX or Gemcitabine as AdjuvantTherapy for Pancreatic Cancer. N Engl J Med., 2018; 379(25): 2395\u20132406.doi: 10.1056\/NEJMoa1809775.","DOI":"10.1056\/NEJMoa1809775"},{"key":"637053r5","doi-asserted-by":"crossref","unstructured":"Jones R.P., Psarelli E.E., Jackson R. et al.: Patterns of Recurrence After Resectionof Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4Randomized Adjuvant Chemotherapy Trial. JAMA Surg., 2019; 154(11): 1038\u2013 1048 doi: 10.1001\/jamasurg.2019.3337.","DOI":"10.1001\/jamasurg.2019.3364"},{"key":"637053r6","doi-asserted-by":"crossref","unstructured":"Groot V.P., Rezaee N., Wu W. et al.: Patterns, Timing, and Predictors of RecurrenceFollowing Pancreatectomy for Pancreatic Ductal Adenocarcinoma. AnnSurg., 2018; 267(5): 936\u2013945. doi: 10.1097\/SLA.0000000000002234.","DOI":"10.1097\/SLA.0000000000002234"},{"key":"637053r7","doi-asserted-by":"crossref","unstructured":"Tanaka M., Mihaljevic A.L., Probst P. et al.: Meta-analysis of recurrence patternafter resection for pancreatic cancer. Br J Surg., 2019; 106(12): 1590\u20131601.doi: 10.1002\/bjs.11295.","DOI":"10.1002\/bjs.11295"},{"key":"637053r8","doi-asserted-by":"crossref","unstructured":"Daamen L.A., Groot V.P., Verkooijen H.M., Molenaar I.Q., van Santvoort H.C.:Response to Comment on: \u201cDetection, Treatment, and Survival of PancreaticCancer Recurrence in the Netherlands: A Nationwide Analysis\u201d. Ann Surg.,2022; 276(6): e1124\u2013e1125. doi: 10.1097\/SLA.0000000000005404.","DOI":"10.1097\/SLA.0000000000005404"},{"key":"637053r9","doi-asserted-by":"crossref","unstructured":"Paniccia A., Hosokawa P., Henderson W. et al.: Characteristics of 10-Year Survivorsof Pancreatic Ductal Adenocarcinoma. JAMA Surg., 2015; 150(8):701\u2013710. doi: 10.1001\/jamasurg.2015.0668","DOI":"10.1001\/jamasurg.2015.0668"},{"key":"637053r10","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma.(Version 2.2025). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1455 (03.02. 2025)."},{"key":"637053r11","doi-asserted-by":"crossref","unstructured":"Conroy T., Pfeiffer P., Vilgrain V. et al.: Pancreatic cancer: ESMO ClinicalPractice Guideline for diagnosis, treatment and follow-up. Ann Oncol., 2023;34(11): 987\u20131002. doi: 10.1016\/j.annonc.2023.08.009.","DOI":"10.1016\/j.annonc.2023.08.009"},{"key":"637053r12","doi-asserted-by":"crossref","unstructured":"Okusaka T., Nakamura M., Yoshida M. et al.: Clinical Practice Guidelines forPancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Int J ClinOncol., 2023; 28(4): 493\u2013511. doi: 10.1007\/s10147-023-02317-x.","DOI":"10.1007\/s10147-023-02317-x"},{"key":"637053r13","doi-asserted-by":"crossref","unstructured":"Khorana A.A., McKernin S.E., Berlin J. et al.: Potentially Curable PancreaticAdenocarcinoma: ASCO Clinical Practice Guideline Update. J Clin Oncol.,2019; 37(23): 2082\u20132088. doi: 10.1200\/JCO.19.00946.","DOI":"10.1200\/JCO.19.00946"},{"key":"637053r14","doi-asserted-by":"crossref","unstructured":"Halle-Smith J.M., Hall L., Daamen L.A. et al.: Clinical benefit of surveillanceafter resection of pancreatic ductal adenocarcinoma: A systematic reviewand meta-analysis. Eur J Surg Oncol., 2021; 47(9): 2248\u20132255. doi: 10.1016\/j.ejso.2021.04.031.","DOI":"10.1016\/j.ejso.2021.04.031"},{"key":"637053r15","doi-asserted-by":"crossref","unstructured":"Andersson R., Ansari D., Haglund C.: Surveillance after resection of pancreaticductal adenocarcinoma: How to do it and what are the benefits? Scand J Surg.,2024; 113(2): 184\u2013185. doi: 10.1177\/14574969231156353.","DOI":"10.1177\/14574969231156353"},{"key":"637053r16","doi-asserted-by":"crossref","unstructured":"Daamen L.A., van Goor I.W.J.M., Groot V.P. et al.: Recurrent disease detectionafter resection of pancreatic ductal adenocarcinoma using a recurrence--focused surveillance strategy (RADAR-PANC): protocol of an internationalrandomized controlled trial according to the Trials within Cohorts design.Trials., 2024; 25(1): 401. doi: 10.1186\/s13063-024-08223-5.","DOI":"10.1186\/s13063-024-08295-3"},{"key":"637053r17","doi-asserted-by":"crossref","unstructured":"Sakamoto T., Yagyu T., Uchinaka E. et al.: Sarcopenia as a prognostic factor inpatients with recurrent pancreatic cancer: a retrospective study. World J SurgOncol., 2020; 18(1): 221. doi: 10.1186\/s12957-020-01981-x.","DOI":"10.1186\/s12957-020-01981-x"},{"key":"637053r18","doi-asserted-by":"crossref","unstructured":"Crippa S., Dom\u00ednguez I., Rodr\u00edguez J.R. et al.: Quality of life in pancreatic cancer:analysis by stage and treatment. J Gastrointest Surg., 2008; 12(5): 783\u2013793;discussion 793\u2013794. doi: 10.1007\/s11605-007-0391-9.","DOI":"10.1007\/s11605-007-0391-9"},{"key":"637053r19","doi-asserted-by":"crossref","unstructured":"Iglesia D., Avci B., Kiriukova M. et al.: Pancreatic exocrine insufficiency andpancreatic enzyme replacement therapy in patients with advanced pancreaticcancer: A systematic review and meta-analysis. United European GastroenterolJ., 2020; 8(9): 1115\u20131125. doi: 10.1177\/2050640620938987.","DOI":"10.1177\/2050640620938987"},{"key":"637053r20","doi-asserted-by":"crossref","unstructured":"Lee J.C., Ahn S., Cho I.K. et al.: Management of recurrent pancreatic cancerafter surgical resection: a protocol for systematic review, evidence mappingand meta-analysis. BMJ Open., 2018; 8(4): e017249. doi: 10.1136\/bmjopen-2017-017249.","DOI":"10.1136\/bmjopen-2017-017249"},{"key":"637053r21","doi-asserted-by":"crossref","unstructured":"Hall W.A., Straza M.W., Chen X. et al.: Initial clinical experience of StereotacticBody Radiation Therapy (SBRT) for liver metastases, primary liver malignancy,and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 Tesla MR-Linac. PLoS One., 2020; 15(8):e0236570. doi: 10.1371\/journal.pone.0236570. Erratum in: PLoS One., 2020;15(11): e0242146. doi: 10.1371\/journal.pone.0242146.","DOI":"10.1371\/journal.pone.0236570"},{"key":"637053r22","doi-asserted-by":"crossref","unstructured":"Comito T., Cozzi L., Zerbi A. et al.: Clinical results of stereotactic body radiotherapy(SBRT) in the treatment of isolated local recurrence of pancreaticcancer after R0 surgery: A retrospective study. Eur J Surg Oncol., 2017; 43(4):735\u2013742. doi: 10.1016\/j.ejso.2016.12.012.","DOI":"10.1016\/j.ejso.2016.12.012"},{"key":"637053r23","doi-asserted-by":"crossref","unstructured":"Mizumoto T., Terashima K., Matsuo Y. et al.: Proton Radiotherapy for IsolatedLocal Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma.Ann Surg Oncol., 2019; 26(8): 2587\u20132594. doi: 10.1245\/s10434-019-07471-z.","DOI":"10.1245\/s10434-019-07471-z"},{"key":"637053r24","doi-asserted-by":"crossref","unstructured":"Ruarus A.H., Vroomen L.G.P.H., Geboers B. et al.: Percutaneous IrreversibleElectroporation in Locally Advanced and Recurrent Pancreatic Cancer(PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. Radiology.,2020; 294(1): 212\u2013220. doi: 10.1148\/radiol.2019191109.","DOI":"10.1148\/radiol.2019191109"},{"key":"637053r25","doi-asserted-by":"crossref","unstructured":"Elliott J.A., Markar S.R., Klevebro F. et al.: An International Multicenter StudyExploring Whether Surveillance After Esophageal Cancer Surgery ImpactsOncological and Quality of Life Outcomes (ENSURE). Ann Surg., 2023; 277(5):e1035\u2013e1044. doi: 10.1097\/SLA.0000000000005378.","DOI":"10.1097\/SLA.0000000000005378"},{"key":"637053r26","doi-asserted-by":"crossref","unstructured":"Deobald R.G., Cheng E.S., Ko Y.J., Wright F.C., Karanicolas P.J.: A qualitativestudy of patient and clinician attitudes regarding surveillance after a resectionof pancreatic and peri-ampullary cancer. HPB (Oxford)., 2015; 17(5): 409\u2013415.doi: 10.1111\/hpb.12378.","DOI":"10.1111\/hpb.12378"},{"key":"637053r27","doi-asserted-by":"crossref","unstructured":"Ansari D., S\u00f8reide K., Andersson B. et al.: Surveillance after surgery for pancreaticcancer: a global scoping review of guidelines and a nordic Survey ofcontemporary practice. Scand J Gastroenterol., 2024; 59(9): 1097\u20131104. doi:10.1080\/00365521.2024.2378948.","DOI":"10.1080\/00365521.2024.2378948"},{"key":"637053r28","doi-asserted-by":"crossref","unstructured":"McKay S.C., Pathak S., Roberts K.J.: Evaluation of post-operative surveillancestrategies and surgeon perceptions and beliefs of surveillance for pancreaticductal adenocarcinoma in the UK. HPB (Oxford)., 2023; 25(10): 1247\u20131254.doi: 10.1016\/j.hpb.2023.06.007.","DOI":"10.1016\/j.hpb.2023.06.007"},{"key":"637053r29","doi-asserted-by":"crossref","unstructured":"Tzeng C.W., Abbott D.E., Cantor S.B. et al.: Frequency and intensity of postoperativesurveillance after curative treatment of pancreatic cancer: a cost-effectivenessanalysis. Ann Surg Oncol., 2013; 20(7): 2197\u20132203. doi: 10.1245\/s10434-013-2889-6.","DOI":"10.1245\/s10434-013-2889-6"},{"key":"637053r30","doi-asserted-by":"crossref","unstructured":"Azizian A., R\u00fchlmann F., Krause T. et al.: CA19-9 for detecting recurrenceof pancreatic cancer. Sci Rep., 2020; 10(1): 1332. doi: 10.1038\/s41598--020-57930-x.","DOI":"10.1038\/s41598-020-57930-x"},{"key":"637053r31","doi-asserted-by":"crossref","unstructured":"Ettrich T.J., Schulte L.A., Eitel N. et al.: Surveillance after resection of pancreaticductal adenocarcinoma with curative intent \u2013 a multicenter survey inGermany and review of the literature. Z Gastroenterol., 2017; 55(7): 657\u2013666.doi: 10.1055\/s-0043-105502.","DOI":"10.1055\/s-0043-105502"},{"key":"637053r32","doi-asserted-by":"crossref","unstructured":"Daamen L.A., Groot V.P., Heerkens H.D. et al.: Systematic review on the roleof serum tumor markers in the detection of recurrent pancreatic cancer. HPB(Oxford)., 2018; 20(4): 297\u2013304. doi: 10.1016\/j.hpb.2017.11.009.","DOI":"10.1016\/j.hpb.2017.11.009"},{"key":"637053r33","doi-asserted-by":"crossref","unstructured":"Jung W., Jang J.Y., Kang M.J. et al.: The clinical usefulness of 18F-fluorodeoxyglucosepositron emission tomography-computed tomography (PET-CT) infollow-up of curatively resected pancreatic cancer patients. HPB (Oxford).,2016; 18(1): 57\u201364. doi: 10.1016\/j.hpb.2015.06.001.","DOI":"10.1016\/j.hpb.2015.06.001"},{"key":"637053r34","doi-asserted-by":"crossref","unstructured":"Mataki Y., Takao S., Maemura K. et al.: Carcinoembryonic antigen messengerRNA expression using nested reverse transcription-PCR in the peripheral bloodduring follow-up period of patients who underwent curative surgery for biliary-pancreatic cancer: longitudinal analyses. Clin Cancer Res., 2004; 10(11):3807\u20133814. doi: 10.1158\/1078-0432.CCR-03-0130.","DOI":"10.1158\/1078-0432.CCR-03-0130"},{"key":"637053r35","doi-asserted-by":"crossref","unstructured":"Safi F., Schlosser W., Kolb G., Beger H.G.: Diagnostic value of CA 19-9 in patientswith pancreatic cancer and nonspecific gastrointestinal symptoms.J Gastrointest Surg., 1997; 1(2): 106\u2013112. doi: 10.1016\/s1091-255x(97)80097-2.","DOI":"10.1016\/S1091-255X(97)80097-2"},{"key":"637053r36","doi-asserted-by":"crossref","unstructured":"Sperti C., Pasquali C., Bissoli S. et al.: Tumor relapse after pancreatic cancerresection is detected earlier by 18-FDG PET than by CT. J Gastrointest Surg.,2010; 14(1): 131\u2013140. doi: 10.1007\/s11605-009-1010-8.","DOI":"10.1007\/s11605-009-1010-8"},{"key":"637053r37","doi-asserted-by":"crossref","unstructured":"Daamen L.A., Groot V.P., Goense L. et al.: The diagnostic performance ofCT versus FDG PET-CT for the detection of recurrent pancreatic cancer:a systematic review and meta-analysis. Eur J Radiol., 2018; 106: 128\u2013136. doi:10.1016\/j.ejrad.2018.07.010.","DOI":"10.1016\/j.ejrad.2018.07.010"},{"key":"637053r38","doi-asserted-by":"crossref","unstructured":"Saponjski D., Djuric-Stefanovic A., Jovanovic M.M. et al.: Utility of MRIin detection of PET-CT proven local recurrence of pancreatic adenocarcinomaafter surgery. Med Oncol., 2024; 41(2): 47. doi: 10.1007\/s12032--023-02271-8.","DOI":"10.1007\/s12032-023-02271-8"},{"key":"637053r39","doi-asserted-by":"crossref","unstructured":"Shin N., Kang T.W., Min J.H. et al.: Utility of Diffusion-Weighted MRI for Detectionof Locally Recurrent Pancreatic Cancer After Surgical Resection. AJRAm J Roentgenol., 2022; 219(5): 762\u2013773. doi: 10.2214\/AJR.22.27739.","DOI":"10.2214\/AJR.22.27739"},{"key":"637053r40","doi-asserted-by":"crossref","unstructured":"Massagu\u00e9 J., Obenauf A.C.: Metastatic colonization by circulating tumour cells.Nature., 2016; 529(7586): 298\u2013306. doi: 10.1038\/nature17038.","DOI":"10.1038\/nature17038"},{"key":"637053r41","doi-asserted-by":"crossref","unstructured":"Bidard F.C., Peeters D.J., Fehm T. et al.: Clinical validity of circulating tumourcells in patients with metastatic breast cancer: a pooled analysis of individualpatient data. Lancet Oncol., 2014; 15(4): 406\u2013414. doi: 10.1016\/S1470-2045(14)70069-5.","DOI":"10.1016\/S1470-2045(14)70069-5"},{"key":"637053r42","doi-asserted-by":"crossref","unstructured":"Lim S.H., Becker T.M., Chua W. et al.: Circulating tumour cells and circulatingfree nucleic acid as prognostic and predictive biomarkers in colorectalcancer. Cancer Lett., 2014; 346(1): 24\u201333. doi: 10.1016\/j.canlet.2013.12.019.","DOI":"10.1016\/j.canlet.2013.12.019"},{"key":"637053r43","doi-asserted-by":"crossref","unstructured":"Antonarakis E.S., Lu C., Luber B. et al.: Clinical Significance of AndrogenReceptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells ofMen With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. J Clin Oncol., 2017;35(19): 2149\u20132156. doi: 10.1200\/JCO.2016.70.1961.","DOI":"10.1200\/JCO.2016.70.1961"},{"key":"637053r44","doi-asserted-by":"crossref","unstructured":"Martini V., Timme-Bronsert S., Fichtner-Feigl S., Hoeppner J., Kulemann B.:Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives. Cancers(Basel)., 2019; 11(11): 1659. doi: 10.3390\/cancers11111659.","DOI":"10.3390\/cancers11111659"},{"key":"637053r45","doi-asserted-by":"crossref","unstructured":"DiPardo B.J., Winograd P., Court C.M., Tomlinson J.S.: Pancreatic cancer circulatingtumor cells: applications for personalized oncology. Expert Rev MolDiagn., 2018; 18(9): 809\u2013820. doi: 10.1080\/14737159.2018.1511429.","DOI":"10.1080\/14737159.2018.1511429"},{"key":"637053r46","doi-asserted-by":"crossref","unstructured":"Hugenschmidt H., Labori K.J., Borgen E. et al.: Preoperative CTC-Detectionby CellSearch Is Associated with Early Distant Metastasis and Impaired Survivalin Resected Pancreatic Cancer. Cancers (Basel)., 2021; 13(3): 485. doi:10.3390\/cancers13030485.","DOI":"10.3390\/cancers13030485"},{"key":"637053r47","doi-asserted-by":"crossref","unstructured":"Safyan R.A., Kim E., Dekker E. et al.: Multidisciplinary Standards and EvolvingTherapies for Patients With Pancreatic Cancer. Am Soc Clin Oncol Educ Book.,2024; 44(3): e438598. doi: 10.1200\/EDBK_438598.","DOI":"10.1200\/EDBK_438598"},{"key":"637053r48","doi-asserted-by":"crossref","unstructured":"Fogel E.L., Shahda S., Sandrasegaran K. et al.: A Multidisciplinary Approach toPancreas Cancer in 2016: A Review. Am J Gastroenterol., 2017; 112(4): 537\u2013554.doi: 10.1038\/ajg.2016.610.","DOI":"10.1038\/ajg.2016.610"},{"key":"637053r49","doi-asserted-by":"crossref","unstructured":"Hsu D.S., Kumar N.S., Le S.T. et al.: Centralization of pancreatic cancer treatmentwithin an integrated healthcare system improves overall survival. AmJ Surg., 2022; 223(6): 1035\u20131039. doi: 10.1016\/j.amjsurg.2021.09.036.","DOI":"10.1016\/j.amjsurg.2021.09.036"},{"key":"637053r50","doi-asserted-by":"crossref","unstructured":"Ladekarl M., Rasmussen L.S., Kirkeg\u00e5rd J. et al.: Disparity in use of moderncombination chemotherapy associated with facility type influences survivalof 2655 patients with advanced pancreatic cancer. Acta Oncol., 2022; 61(3):277\u2013285. doi: 10.1080\/0284186X.2021.2012252.","DOI":"10.1080\/0284186X.2021.2012252"}],"container-title":["Polish Journal of Surgery"],"original-title":[],"link":[{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0055.6328","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0055.6328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:50:15Z","timestamp":1786369815000},"score":1,"resource":{"primary":{"URL":"https:\/\/ppch.pl\/gicid\/01.3001.0055.6328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,1,22]]}},"URL":"https:\/\/doi.org\/10.5604\/01.3001.0055.6328","relation":{},"ISSN":["0032-373X","2299-2847"],"issn-type":[{"value":"0032-373X","type":"print"},{"value":"2299-2847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}